However, a higher frequency of BRCA1/2 mutations was identified among patients with the tumor BRCA test requested at least 6 months after diagnosis without disease-relapse (34.3%) as compared with patients with the test performed at diagnosis or disease relapse (29.3% and 16.2%, respectively). Here, BRCA1 is linked to neoplasm.